Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
VA Greater Los Angeles Healthcare System PriCara, Unit of Ortho-McNeil, Inc. Eisai Inc. |
---|---|
Information provided by: | VA Greater Los Angeles Healthcare System |
ClinicalTrials.gov Identifier: | NCT00304421 |
The purpose of the study is to compare the effect of two different drugs, rabeprazole (20 mg) and pantoprazole (40 mg), and their effects on the amount of acid produced by your stomach on evening and at night after standard protein meal.
Condition | Intervention | Phase |
---|---|---|
Gastroesophageal Reflux Disease |
Drug: rabeprazole Drug: pantoprazole |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Pharmacokinetics Study |
Official Title: | Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD |
Estimated Enrollment: | 23 |
Study Start Date: | January 2004 |
Study Completion Date: | September 2007 |
Gastric acid secretion can be divided into two phases: the daytime phase and the nocturnal phase. Nocturnal acid reflux is presumably more damaging because of loss of salivary neutralization. The present study is designed to measure effects of rabeprazole and pantoprazole on post-prandial and nocturnal gastric acid secretion and intragastric pH in H. pylori-negative volunteers with gastroesophageal reflux disease. These measurement will be used to compare the degree of inhibition of gastric acid secretion between the two drugs.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
VA Greater Los Angeles Healthcare System | |
Los Angeles, California, United States, 90073 |
Principal Investigator: | Joseph Pisegna, MD | VA Greater Los Angeles Healthcare System |
Study ID Numbers: | 0028 |
Study First Received: | March 16, 2006 |
Last Updated: | September 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00304421 History of Changes |
Health Authority: | United States: Federal Government |
Gastroesophageal Reflux Disease Proton Pump Inhibitors Gastric pH Gastric Acid Secretion |
Deglutition Disorders Esophageal Motility Disorders Digestive System Diseases Proton Pump Inhibitors Esophageal Disorder |
Gastrointestinal Diseases Pantoprazole Esophageal Diseases Gastroesophageal Reflux Rabeprazole |
Molecular Mechanisms of Pharmacological Action Gastrointestinal Diseases Pantoprazole Gastrointestinal Agents Enzyme Inhibitors Gastroesophageal Reflux Pharmacologic Actions |
Esophageal Motility Disorders Deglutition Disorders Digestive System Diseases Therapeutic Uses Anti-Ulcer Agents Esophageal Diseases Rabeprazole |